Affymetrix Inc. and Reveal Biosciences LLC, an advanced tissue technologies company, announced a partnership agreement through which Reveal will use Affymetrix ViewRNA ISH products for tissue samples to provide RNA in situ hybridization (ISH) staining, imaging, and quantification services using the company’s proprietary image analysis software, ImageDx.

“RNA in situ hybridization is fast becoming the method of choice for researchers wanting to validate established and novel biomarkers for translational and clinical research,” said Guy Afseth, marketing director for Affymetrix’ oncology portfolio. With Affymetrix’ ViewRNA ISH portfolio for tissue samples, researchers can rapidly design assays for virtually any mRNA transcript or long noncoding RNA in any tissue type. ViewRNA assays utilize branched DNA signal amplification technology to achieve unparalleled sensitivity and specificity, enabling the visualization of targets at the single-molecule level within the context of the tissue morphology.

“We are thrilled to partner with Affymetrix to provide high-quality services using ViewRNA products. Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software, ImageDx, form a powerful platform for the localization and quantification of mRNA in tissue samples,” said Dr. Claire Weston, CEO and founder of Reveal Biosciences. “This highly sensitive technology is changing the face of mRNA biomarker screening and analysis for translational research and diagnostics.”

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness.